KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EBITDA (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed EBITDA for 9 consecutive years, with $244.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 968.9% year-over-year to $244.7 million, compared with a TTM value of $263.0 million through Dec 2025, up 394.5%, and an annual FY2025 reading of $263.0 million, up 394.5% over the prior year.
  • EBITDA was $244.7 million for Q4 2025 at Biocryst Pharmaceuticals, up from $12.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $244.7 million in Q4 2025 and bottomed at -$200.5 million in Q4 2023.
  • Average EBITDA over 3 years is -$3.0 million, with a median of -$12.3 million recorded in 2024.
  • The sharpest move saw EBITDA skyrocketed 85.95% in 2024, then surged 968.9% in 2025.
  • Year by year, EBITDA stood at -$200.5 million in 2023, then soared by 85.95% to -$28.2 million in 2024, then soared by 968.9% to $244.7 million in 2025.
  • Business Quant data shows EBITDA for BCRX at $244.7 million in Q4 2025, $12.4 million in Q3 2025, and $5.6 million in Q2 2025.